miércoles, 28 de junio de 2017

Bibliografía Clave de Vandetanib en Cáncer Medular de Tiroides

  1. Wells SA Jr, Robinson BG, Gagel RF, et al. Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial. J Clin Oncol 2012;30(2):134-41
  2. Wells SA Jr, Gosnell JE, Gagel RF, et al. Vandetanib for the treatment of patients with locally advanced or metastatic hereditary medullary thyroid cancer. J Clin Oncol;28(5):767-72
  3. Koch L. Pharmacotherapy: vandetanib-a new therapeutic option in advanced medullary thyroid cancer. Nat Rev Endocrinol 2011 Nov 15;8(1):1
  4. Thornton K, Kim G, Maher VE, et al. Vandetanib for the treatment of symptomatic or progressive medullary thyroid cancer in patients with unresectable locally advanced or metastatic disease: U.S. Food and Drug Administration drug approval summary. Clin Cancer Res 2012;18(14):3722-30
  5. Frampton JE. Vandetanib: in medullary thyroid cancer. Drugs 2012;72(10):1423-36
  6. Degrauwe N, Sosa JA, Roman S, Deshpande HA. Vandetanib for the treatment of metastatic medullary thyroid cancer. Clin Med Insights Oncol 2012;6:243-52

Teléfono de Información Científica y de Productos de Astra Zeneca 900 200 444 (Llamada gratuita)

Ficha técnica:
http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/002315/human_med_001529.jsp&mid=WC0b01ac058001d124


 Principales Guías Clínicas de Tratamiento del CMT  <<   Volver al apartado anterior